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Role of the CHADS2 Score in the Evaluation
of Thromboembolic Risk in Patients With
Atrial Fibrillation Undergoing Transesophageal
Echocardiography Before Pulmonary Vein Isolation
Sarinya Puwanant, MD,*† Brandon C. Varr, BS,* Kevin Shrestha, AB,* Sarah K. Hussain, MD,*
W. H. Wilson Tang, MD,* Ruvin S. Gabriel, MD,* Oussama M. Wazni, MD,* Mandeep Bhargava, MD,*
Walid I. Saliba, MD,* James D. Thomas, MD,* Bruce D. Lindsay, MD,* Allan L. Klein, MD*
Cleveland, Ohio; and Bangkok, Thailand
Objectives The goals of this study were to determine: 1) if low-risk patients assessed by a CHADS2 score, a clinical scoring sys-
tem quantifying a risk of stroke in patients with atrial fibrillation (AF), require a routine screening transesophageal
echocardiogram (TEE) before pulmonary vein isolation (PVI); and 2) the relationship of a CHADS2 score with left atrial
(LA)/left atrial appendage (LAA) spontaneous echo contrast, sludge, and thrombus.
Background There is no clear consensus of whether a screening TEE before catheter ablation of AF should be performed in
every patient.
Methods Initial TEEs for pre-PVI of 1,058 AF patients (age 57  11 years, 80% men) were reviewed and compared with a
CHADS2 score.
Results CHADS2 scores of 0, 1, 2, 3, 4, 5, and 6 were present in 47%, 33%, 14%, 5%, 1%, 0.3%, and 0% of patients,
respectively. The prevalence of LA/LAA thrombus, sludge, and spontaneous echo contrast were present in 0.6%,
1.5%, and 35%. The prevalence of LA/LAA thrombus/sludge increased with ascending CHADS2 score (scores 0
[0%], 1 [2%], 2 [5%], 3 [9%], and 4 to 6 [11%], p  0.01). No patient with a CHADS2 score of 0 had LA/LAA
sludge/thrombus. In a multivariate model, history of congestive heart failure and left ventricular ejection fraction
35% were significantly associated with sludge/thrombus.
Conclusions The prevalence of LA/LAA sludge/thrombus in patients with AF undergoing a pre-PVI screening TEE is very low
(2%) and increases significantly with higher CHADS2 scores. This suggests that a screening TEE before PVI
should be performed in patients with a CHADS2 score of 1, and in patients with a CHADS2 score of 0 when the
AF is persistent and therapeutic anticoagulation has not been maintained for 4 weeks before the
procedure. (J Am Coll Cardiol 2009;54:2032–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.037C
p
p
p
a
w
s
p
s
Aatheter ablation has emerged as an established strategy for
restoration of sinus rhythm in patients with atrial fibril-
ation (AF) (1–4). Recent studies have shown that catheter
blation of AF was associated with thromboembolic events,
ith most events occurring within 2 weeks after the proce-
ure (5). The ablation procedure leaves patients with scar
nd endothelial injury, which creates a thrombogenic milieu
eading to thrombus formation. The 2007 Heart Rhythm
ociety/European Heart Rhythm Association/European
rom the *Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
hio; and the †Division of Cardiology, Department of Medicine, Chulalongkorn
niversity, Bangkok, Thailand. Dr. Wazni serves as a consultant for Biosensep
ebster.
Manuscript received June 16, 2009; accepted July 8, 2009.ardiac Arrhythmia Society guidelines (6) recommend
erforming pre-procedural transesophageal echocardiogra-
hy (TEE) screening for the presence of thrombus in
atients with persistent AF who are in AF at the time of
blation (6). However, there is no clear consensus of
hether screening TEE before catheter ablation of AF
hould be performed in every patient.
See page 2040
The aims of this study were: 1) to determine if low-risk
atients with AF assessed by a CHADS2 score, a clinical
coring system quantifying a risk of stroke in patients with
F, necessarily require a routine screening TEE before
ulmonary vein antral isolation (PVI); 2) to determine the
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November 24, 2009:2032–9 CHADS2 Score and TEE in Pulmonary Vein Isolationelationship of a CHADS2 score with pre-procedural left
trial (LA)/left atrial appendage (LAA) characteristics of
hrombogenic milieu identified by a TEE; and 3) to
etermine the prevalence of LA/LAA thrombus and/or
ludge in these patients.
ethods
atients. From January 1999 to December 2006, 1,208
onsecutive patients with AF who underwent TEE for pre-
VI screening at Cleveland Clinic were identified from Cleve-
and Clinic Echocardiography and Electrophysiology data-
ases. We excluded 125 subsequent TEEs on the same
atients (only the initial TEE was used for analysis when a
atient underwent TEE more than once during study period)
nd 25 patients who did not have available CHADS2 score
ata for analysis. A total of 1,058 patients were included in the
tudy. The study was approved by the Cleveland Clinic
nstitutional Review Board.
A retrospective medical record review was performed by an
bserver blinded to echocardiographic findings. The clinical
ata were reviewed beginning 3 months before TEE. A
HADS2 score (7,8) ranging from 0 to 6 was calculated for
ach patient at the time of TEE as: congestive heart failure
CHF) (1 point); hypertension (1 point); age 75 years (1
oint); and history of stroke, transient ischemic attack (TIA),
r systemic embolism (2 points). A low thromboembolic risk
as defined as a CHADS2 score of 0 to 1. A history of
oronary artery disease, thyrotoxicosis, obstructive sleep apnea,
hronic obstructive pulmonary disease, cardiomyopathy, prior
blative procedure or direct current cardioversion (DCC), the
se of systemic anticoagulation, the cardiac rhythm at the time
f PVI and the findings on TEE in the case that the PVI was
ancelled or deferred, and the classification of AF were re-
iewed. Paroxysmal atrial fibrillation (PAF) was defined as
ecurrent AF (2 episodes) that terminates spontaneously
ithin 7 days (6,9). Persistent AF was defined as AF that is
ustained beyond 7 days, or lasting 7 days but necessitating
harmacologic or electrical cardioversion (6,9). Persistent AF
lso included longstanding persistent AF (continuous AF of
1-year duration). Permanent AF was defined as AF in which
ardioversion has either failed or not been attempted (6,9). In
atients who had AF episodes that fell into 1 or more of these
ategories, their most frequent pattern of AF was used.
EE. TEE was performed using commercially available
quipment equipped with a multiplane phase array trans-
ucer. All TEEs were performed within 24 h before the
VI procedure, including procedures cancelled due to LA/
AA thrombus or sludge. All patients gave written consent
efore TEE. Lidocaine was used for local anesthesia of
ypopharynx. Conscious sedation with intravenous midazo-
am and/or fentanyl was given in all patients. Standard
sophageal intubation and TEE acquisition were conducted
10). Cine loop of LA and LAA from 0° to 180° was stored
or offline analysis. lchocardiographic data analy-
is. TEEs were reviewed for the
resence of LA/LAA, spontane-
us echo contrast (SEC), sludge,
nd thrombus by 2 observers who
ere blinded to clinical history.
nterobserver differences were re-
olved by a third observer.
SEC was defined as dynamic
smoke-like” echoes with the
haracteristic swirling motion
ith optimal gain setting during
ardiac cycle (11,12). Sludge was
efined as a dynamic gelatinous,
recipitous echodensity, without
discrete mass, present through-
ut the cardiac cycle (11). Throm-
us was defined as circumscribed
nd uniformly echodense intracav-
tary mass distinct from the under-
ying LA or LAA endocardium
nd the pectinate muscles, and
resent in more than 1 imaging
lane (11,13).
nticoagulation and catheter
blative procedure. In our in-
titution, we routinely perform
his procedure while patients are fully anticoagulated, with a
herapeutic international normalized ratio (INR) between 2
nd 3.5 (14–16). INRs are usually checked every 3 weeks for
t least 3 months before the PVI. In the 3 weeks just before
he PVI, the INRs are checked on a weekly basis. At our
nstitution, patients are almost always anticoagulated for at
east 3 months before the PVI; however, the anticoagulant
egimen has changed over the course of the 7-year study
eriod. From January 1999 to December 2005, anticoagu-
ation was usually discontinued for 3 to 4 days before the
VI. Since 2006, anticoagulation was continued until the
ime of the PVI. The TEEs are done during the day of the
VI. Patients with chronic AF must have therapeutic INRs
or at least 2 to 3 months before the procedure. Heparin
olus (100 to 150 U/kg) is always given before transseptal
unctures. The patient is maintained on a heparin infusion
ate of 15 to 20 U/kg/h (14,15) and the infusion rate is
djusted to keep the activated clotting time in the range of
50 to 450 s. The PVI procedure was performed according to
standard measure as previously described elsewhere
3,4,6,17,18). There is no consensus in the management of
A/LAA sludge. The decision of whether the PVI procedure
hould be further continued, deferred, or cancelled after a
creening TEE was individually based on the judgment of the
lectrophysiologist.
tatistical analysis. The frequency and percentage of TEE
haracteristics of the thrombogenic milieu (SEC, sludge,
hrombus) and mean SD of LAA emptying velocities and
Abbreviations
and Acronyms
AF  atrial fibrillation
CHF  congestive heart
failure
CT  computed
tomography
DCC  direct current
cardioversion
INR  international
normalized ratio
LA  left atrial
LAA  left atrial
appendage
LVEF  left ventricular
ejection fraction
PAF  paroxysmal atrial
fibrillation
PVI  pulmonary vein
isolation
SEC  spontaneous echo
contrast
TEE  transesophageal
echocardiogram
TIA  transient ischemic
attackeft ventricular ejection fraction (LVEF) were reported in
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CHADS2 Score and TEE in Pulmonary Vein Isolation November 24, 2009:2032–9ach CHADS2 score and in each classification of AF (PAF
ith sinus rhythm at the time of PVI, PAF with AF at the
ime of PVI, and persistent/permanent AF). TEE charac-
eristics and continuous variables were compared across level
atient Characteristics of,058 TEE P rticipant Before PVITable 1 Pa ient Characteristics of1,058 TEE Participants Before PVI
Total Patients (n  1,058)
Age, yrs 57 11
Men 842 (80%)
Congestive heart failure 140 (13%)
Hypertension 425 (40%)
Diabetes mellitus 91 (9%)
Stroke/TIA/systemic embolic events 88 (8%)
Coronary artery disease 169 (16%)
Obstructive sleep apnea 78 (7%)
Thyrotoxicosis/hyperthyroidism 13 (1%)
Left ventricular ejection fraction 35% 93 (9%)
Prior pulmonary vein isolation 172 (16%)
Prior maze 19 (2%)
Prior cardioversion 478 (45%)
Anticoagulation at the time of TEE 775 (73%)
CHADS2 score
0 498 (47%)
1 346 (33%)
2 143 (14%)
3 53 (5%)
4 14 (1%)
5 4 (0.3%)
6 0 (0%)
LA/LAA spontaneous echo contrast 374 (35%)
LA/LAA sludge 16 (1.5%)
LA/LAA thrombus 6 (0.6%)
Paroxysmal AF 881 (81%)
Persistent AF 192 (18%)
Permanent AF 5 (0.6%)
Bio/mechanical prosthesis 13 (1%)/10 (1%)
Rheumatic heart disease 3 (0.3%)
Mitral and aortic valve disease (2) 116 (11%)
BNP (pg/ml) 138 161
hsCRP (mg/l) 3.7 12.4
F atrial fibrillation; BNP brain natriuretic peptide; hsCRP highly sensitive C-reactive protein;
A  left atrial; LAA  left atrial appendage; PVI  pulmonary vein isolation; TEE  transesoph-
geal echocardiogram; TIA  transient ischemic attack.
ransesophageal Echocardiographic Correlates of ThromboembolicTable 2 Transesophageal Echocardiographic Correlates of Thro
0 (n  498) 1 (n  3
LAA SEC* 121 (24%) 115 (33
LAA sludge* 0 (0%) 4 (2%
LAA thrombus† 0 (0%) 4 (1%
LAA sludge and thrombus* 0 (0%) 8 (2%
LAA emptying velocities (cm/s)* 49 20 (15–100) 41 21 (15
LVEF (%)† 53 7 (15–65) 50 11 (5–
NSR at time of PVI/TEE* 120 (24%) 78 (23
Paroxysmal AF 411 (83%) 282 (82p  0.01; †p  0.03.
LVEF  left ventricular ejection fraction; NSR  normal sinus rhythm; SEC  spontaneous echo contraf CHADS2 score and 3 AF classification groups using the
hi-square or Fisher exact test as appropriate and analysis of
ariance test, respectively. Multivariable logistic regression
as performed to identify independent clinical predictors of
A/LAA thrombus and sludge. The variables tested in the
ogistic model include CHADS2 score 2, persistent/
ermanent AF, hypertension, prior stroke/TIA/systemic
mboli, LVEF 35%, CHF, diabetes mellitus, age 75
ears, AF at the time of PVI, previous cardioversion,
revious PVI, coronary artery disease, and INR 2. Statis-
ical significance was defined as p  0.05.
eproducibility. To determine the intra- and interob-
erver variation, echocardiographic data (control data [n 
], SEC [n  5], sludge [n  5], and thrombus [n  5])
rom a nested case group of 20 randomly selected patients
ere analyzed by the same observer at 2 points in time at
east 4 weeks apart in a blinded fashion. The same nested
ample was reviewed in a similar manner on 2 occasions by
second observer. A kappa statistic analysis was used to
escribe agreement.
esults
atient characteristics are shown in Table 1. The mean age
f participants was 57  11 years; 80% were men. Most
81%) had PAF, and 73% were anticoagulated at the time of
VI/TEE. Impaired left ventricular function (LVEF
35%) was present in 9% of patients. The majority of
atients (80%) were in a low-risk group as CHADS2 scores
f 0 and 1 were present in 47% and 33%, respectively. Of
tudied patients, 1% (n  10) had mechanical prosthesis
scores 0 [15%], 1 [23%], 2 [23%], 3 [31%], and 4 to 6
8%]), and 0.3% (n  3) had rheumatic heart diseases
scores 0 [0%], 1 [33%], 2 [33%], 3 [0%], and 4 to 6 [33%]).
revalence of LA/LAA thrombus or sludge. Among
,058 patients who underwent screening TEE before PVI,
he prevalence of LA/LAA thrombus and sludge were only
.6% (n  6) and 1.5% (n  16), respectively. The PVI
rocedures were cancelled in 6 and 7 patients due to
A/LAA thrombus and sludge, respectively.
(CHADS2 Score)mbolic Risk (CHADS2 Score)
CHADS2 Score
2 (n  143) 3 (n  53) 4 to 6 (n  18)
84 (59%) 39 (74%) 15 (83%)
6 (4%) 5 (9%) 1 (6%)
1 (2%) 0 (0%) 1 (6%)
7 (5%) 5 (9%) 2 (11%)
30 17 (11–73) 40 21 (10–68) 22 15 (11–32)
51 11 (15–65) 48 12 (20–65) 50 11 (20–60)
20 (14%) 5 (9%) 2 (11%)
115 (80%) 39 (74%) 4 (78%)Riskmboe
46)
%)
)
)
)
–100)
65)
%)
%)st; other abbreviations as in Table 1.
R
t
p
C
4
w
s
o
o
p
p
(
d
C
i
i
a
f
i
p
(
R
w
c
p
r
I
s
L
L
F
p
F
(
m
p
2
t
iv
id
ua
l
C
lin
ic
al
an
d
Ec
ho
ca
rd
io
gr
ap
hi
c
C
ha
ra
ct
er
is
ti
cs
of
P
at
ie
nt
s
W
it
h
C
H
A
D
S
2
S
co
re
of
1
an
d
LA
/
LA
A
S
lu
dg
e
or
Th
ro
m
bu
s
ab
le
3
In
di
vi
du
al
C
lin
ic
al
an
d
Ec
ho
ca
rd
io
gr
ap
hi
c
C
ha
ra
ct
er
is
ti
cs
of
P
at
ie
nt
s
W
it
h
C
H
A
D
S
2
S
co
re
of
1
an
d
LA
/
LA
A
S
lu
dg
e
or
Th
ro
m
bu
s
at
ie
nt
#
A
ge
,
yr
s
S
ex
TE
E
C
H
F
H
TN
D
M
C
H
A
D
S
2
S
co
re
P
ri
or
S
tr
ok
e/
TI
A
C
om
or
bi
d
D
is
ea
se
P
ri
or
P
V
I/
M
az
e
P
ri
or
D
C
C
LV
EF
(%
)
A
C
IN
R
Ty
pe
of
A
F
R
hy
th
m
on
P
V
I
D
at
e/
TE
E
S
ub
se
qu
en
t
Ev
en
ts
Ev
en
t
Fo
llo
w
-U
p
(D
ay
s)
LA
A
V
(c
m
/
s)
1
5
0
M
S
LU
N
o
Ye
s
N
o
1
N
o
H
C
M
0
2
5
5
Ye
s
—
P
A
F
A
F
0
1
,8
0
5
5
0
2
6
5
M
S
LU
Ye
s
N
o
N
o
1
N
o
C
A
D
0
1
3
0
Ye
s
—
C
A
F
N
S
R
0
2
4
0
N
A
3
4
9
M
S
LU
Ye
s
N
o
N
o
1
N
o
H
C
M
0
1
5
0
Ye
s
1
.4
P
A
F
A
F
0
9
3
6
2
5
4
6
1
M
S
LU
N
o
Ye
s
N
o
1
N
o
N
o
0
0
3
5
Ye
s
2
.5
C
A
F
A
F
S
tr
ok
e
0
2
0
5
6
7
M
LA
T
Ye
s
N
o
N
o
1
N
o
C
O
P
D
,C
A
D
0
0
1
5
Ye
s
1
.9
P
A
F
A
F
0
2
8
4
2
6
6
6
1
F
LA
T
Ye
s
N
o
N
o
1
N
o
N
o
1
2
5
5
Ye
s
2
.5
P
A
F
A
F
0
1
,4
2
0
4
0
7
4
4
M
LA
T
Ye
s
N
o
N
o
1
N
o
N
o
0
0
5
Ye
s
1
.4
C
A
F
A
F
0
3
0
N
A
8
6
5
M
LA
T
Ye
s
N
o
N
o
1
N
o
N
o
1
0
5
5
Ye
s
1
.8
P
A
F
N
S
R
0
5
3
5
N
A
an
tic
oa
gu
la
tio
n;
C
A
D

co
ro
na
ry
ar
te
ry
di
se
as
e;
C
A
F

ch
ro
ni
c
at
ri
al
fib
ri
lla
tio
n;
C
H
F

co
ng
es
tiv
e
he
ar
t
fa
ilu
re
;C
O
P
D

ch
ro
ni
c
ob
st
ru
ct
iv
e
pu
lm
on
ar
y
di
se
as
e;
D
C
C

di
re
ct
cu
rr
en
t
ca
rd
io
ve
rs
io
n;
D
M

di
ab
et
es
m
el
lit
us
;F

fe
m
al
e;
F/
U

fo
llo
w
-u
p;
H
C
M

rt
ro
ph
ic
ca
rd
io
m
yo
pa
th
y;
H
TN

hy
pe
rt
en
si
on
;I
N
R

in
te
rn
at
io
na
ln
or
m
al
iz
ed
ra
tio
;L
A
A
V

le
ft
at
ri
al
ap
pe
nd
ag
e
em
pt
yi
ng
ve
lo
ci
ty
;L
A
T

le
ft
at
ri
al
/l
ef
t
at
ri
al
ap
pe
nd
ag
e
th
ro
m
bu
s;
LV
EF

le
ft
ve
nt
ri
cu
la
r
ej
ec
tio
n
fr
ac
tio
n;
M

m
al
e;
N
S
R

no
rm
al
si
nu
s
rh
yt
hm
;

pa
ro
xy
sm
al
at
ri
al
fib
ri
lla
tio
n;
S
LU

sl
ud
ge
;o
th
er
ab
br
ev
ia
tio
ns
as
in
Ta
bl
e
1
.
2035JACC Vol. 54, No. 22, 2009 Puwanant et al.
November 24, 2009:2032–9 CHADS2 Score and TEE in Pulmonary Vein Isolationelationship of CHADS2 score and TEE features of a
hrombogenic milieu. As demonstrated in Table 2, the
revalence of thrombus/sludge increased with ascending
HADS2 scores (scores 0 [0%], 1 [2%], 2 [5%], 3 [9%], and
to 6 [11%], p  0.01). Peak LAA emptying velocities
ere also significantly reduced with ascending CHADS2
core. No patients with a CHADS2 score of 0, irrespective
f LVEF and classification of AF, had LA/LAA thrombus
r sludge. LA/LAA thrombus or sludge was present in 8
atients (2%) with a CHADS2 score of 1 who were
resumed to be at a relatively low risk of stroke
Fig. 1). Table 3 details the individual clinical and echocar-
iographic characteristics in those low-risk patients with a
HADS2 score of 1 who had LA/LAA sludge or thrombus
dentified on TEE. Four of these patients (50%) had
mpaired LVEF, and 7 of these patients (88%) were in AF
t the time of PVI. None of these patients had clinical risk
actors of diabetes or prior stroke/TIA. Figures 2 and 3
llustrate LA/LAA findings of sludge and thrombus in
atients with CHADS2 scores of 1 (Patients #4 and #7)
Table 3).
elationship of CHADS2 score and classification of AF
ith TEE features of a thrombogenic milieu. As indi-
ated in Table 4, LA/LAA thrombus and sludge were
resent in 1% of patients with PAF with normal sinus
hythm at the time of PVI.
ndependent clinical predictors of LA/LAA thrombus or
ludge. In the multivariable model, a history of CHF and
VEF 35% was only significantly associated with LA/
AA thrombus/sludge (Table 5).
ollow-up thromboembolic events. In our study, the
atients were anticoagulated post-PVI for at least 3 months.
ollow-up data were available in 1,039 of 1,058 patients
98%) with a mean follow-up duration of 60.9  53.7
onths. Of 1,039 patients, 19 (1.8%) and 2 (0.02%)
atients had ischemic stroke and TIA, respectively. One of
2 (5%) patients with LA/LAA thrombus/sludge at the
ime of PVI/TEE developed post-PVI thromboembolic
Figure 1 CHADS2 Score
This figure illustrates the prevalence of transesophageal
echocardiogram characteristics relative to CHADS scores.2In
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CHADS2 Score and TEE in Pulmonary Vein Isolation November 24, 2009:2032–9troke whereas 21 of 1,017 (2%) patients without LA/LAA
hrombus/sludge developed post-PVI thromboembolic
troke; however, this was not statistically significant (p 
.48).
Figure 2 LAA Sludge Identified on Pre-PVI
TEE in a Patient With a CHADS2 Score of 1
Multiplane transesophageal echocardiogram (TEE) at 65° demonstrates left
atrial appendage (LAA) sludge (arrowheads). The shape of precipitous
echodensity is dynamically changed and transformed into different patterns
during the cardiac cycle (A to D). This patient (Patient #4) (Table 3) had per-
sistent atrial fibrillation and a CHADS2 score of 1. Unfortunately, the patient
suffered from stroke immediately after pulmonary vein isolation (PVI). LA  left
atrial; LV  left ventricle.
Figure 3 LAA Thrombus Identified on Pre-PVI
TEE in a Patient With a CHADS2 Score of 1
Multiplane TEE at 63° demonstrates an LAA thrombus (arrows). This patient
(Patient #7) (Table 3) had persistent atrial fibrillation and a CHADS2 score of
1. Abbreviations as in Figure 2. *nterobserver variability. To determine the intraobserver
nd interobserver variation, echocardiographic data (control
ata [n  5], SEC [n  5], sludge [n  5], and thrombus
n  5]) from a nested case group of 20 randomly selected
atients were analyzed by the same observer at 2 points in
ime at least 4 weeks apart in a blinded fashion. The same
ested sample was reviewed in a similar manner on 2
ccasions by a second observer. The concordance between 2
bservers in identification of LA/LAA characteristics of
hrombogenic milieu was high (overall kappa  0.933). No
iscordance between thrombus and sludge was demon-
trated. The intraobserver concordance was very high as well
kappa  1.00).
iscussion
he major findings of our study are: 1) the yield of
A/LAA thrombus/sludge identified on TEE in patients
ith AF referred for pre-PVI TEE screening was very low
0.6% for thrombus and 1.5% for sludge); 2) LA/LAA
hrombus or sludge was present in only patients with at least
clinical risk factor(s) (CHADS2 score of 1); 3) the
revalence of LA/LAA thrombus/sludge significantly in-
reased with increasing CHADS2 score; and 4) in addition
o CHADS2 score, a history of CHF and LVEF 35%
ere independent predictors of the presence of LA/LAA
hrombus/sludge in these patients. The implication is that
EEs are not needed to assess stroke risk in patients with a
HADS2 score of 0 when the therapeutic anticoagulation
ransesophageal Echocardiographic Characteristicsf Patients With Paroxysmal and Patients Withersist t AF
Table 4
Transes ph geal Echo ardiographic Characteristics
of Patients With Paroxysmal and Patients With
Persistent AF
Paroxysmal AF
NSR at PVI*
(n  207)
Paroxysmal AF
AF at PVI*
(n  654)
Persistent/
Permanent AF
(n  197)
SEC† 26% 37% 40%
Sludge† 0.5% 1% 3%
Thrombus 0.5% 1% 3%
Sludge/thrombus† 1% 2% 5%
Cardiac rhythm was assessed at the time of transesophageal echocardiogram in only cases that
ulmonary vein isolation (PVI) was cancelled due to left atrial/left atrial appendage thrombus/
ludge; †p  0.05.
AF  atrial fibrillation; other abbreviations as in Table 2.
linical Characteristic Predictor ofA/LAA Sludge/Thrombus: Multivariate AnalysisTable 5 Clinical Cha acteristic Predictor ofLA/LAA Sludge/Thrombus: Multivariate Analysis
Clinical Variables Odds Ratio 95% Confidence Interval
CHADS2 score 2 1.5 0.11–18.50
Prior stroke/TIA/systemic emboli 2.8 0.38–22.99
LVEF 35%* 5.2 1.11–24.83
Congestive heart failure* 29.2 4.69–298.86
Diabetes mellitus 1.8 0.21–14.15
AF at time of PVI 1.2 0.18–11.44
International normalized ratio 2 1.3 0.28–6.16Significant variables.
LVEF  left ventricular ejection fraction; other abbreviations as in Table 1.
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iographic findings associated with increased risk of stroke
n patients with a CHADS2 score 1.
revalence of LA/LAA thrombus or sludge. The pres-
nce of LA/LAA thrombus is associated with an increased
isk of thromboembolic events (11,19,20). Our findings of
he low prevalence of pre-procedural LA/LAA thrombus
0.6%) agreed with the previous report by Khan et al. (21)
ho studied 601 patients with AF at our institution and
howed that the prevalence of LA/LAA thrombus was
1%. However, our study population was larger. Khan et al.
21) did not describe whether they excluded patients with
ubsequent TEEs on the same patients. In contrast to our
tudy, they included all patients with TEE regardless of
vailable CHADS2 score data for analysis. Furthermore, we
ave reassessed all TEE studies blinded to CHADS2 score
hereas their study used TEE reports from the medical
ecords. Additionally, our database includes the TEE pa-
ients regardless of computed tomography (CT) scan, but
heir database includes the CT patients and the patients
ho had both TEE/CT. Champagne et al. (22) reported
hat LA thrombus was present in only 1 patient among 85
1%) that underwent TEE-guided AF ablation. However,
ompared with patients with AF undergoing TEE before
CC, the prevalence of LA/LAA thrombus in our study
opulation was far less frequent (12% vs. 0.6%) (20,23). A
otential explanation for the low prevalence of LA/LAA
hrombus in our study was the fact that the majority of studied
atients (80%) were in a low-risk (CHADS2 score 1) group
nd were anticoagulated (73%).
The clinical significance of LA/LAA “sludge” (11,24) has
ot been well described. Our investigators have previously
eported that the mortality and thromboembolic risk in AF
atients with sludge were comparable to those with throm-
us and could be considered as a contraindication to DCC
nd PVI (25). Similar to the prevalence of LA/LAA
hrombus, the prevalence of sludge was low (1.5%). Our
ndings suggest that a more selective TEE approach to
arget high-risk patients could be implemented.
elective TEE approach stratified by a CHADS2 score.
he CHADS2 score, a clinical scoring system quantifying a
isk of stroke in patients with AF, was recently devised and
alidated in 1,733 Medicare beneficiaries with nonvalvular
F (7) and in 51,807 general practice research database
atients with chronic AF in the United Kingdom (8),
espectively. The CHADS2 scoring scheme was found to be
good predictor of stroke risk, with higher scores associated
ith an increased stroke rate (7,8). In our cohort, it was
nteresting that no patients with a CHADS2 score of 0 had
A/LAA thrombus or sludge identified on TEE. However,
ur findings were in contrast to those of Rader et al. (26)
nd Zabalgoitia et al. (27). Rader et al. (26) previously
eported that LA/LAA thrombus was identified in 2 pa-
ients with nonvalvular AF and a CHADS2 score of 0 (70
nd 74 years old; only 1 of them received anticoagulation).
t was noted that overall, fewer patients in their study were dnticoagulated (69% vs. 73%) and the prevalence of clinical
isk factors (heart failure, hypertension, diabetes, stroke, and
mpaired left ventricular function) was higher than those in
ur study. Additionally, they excluded patients in sinus
hythm at the time of TEE, and their study did not target
atients undergoing PVI. These factors may have affected
he characteristics of the thrombogenic milieu resulting in
ifferent findings. Similar to the study of Rader et al. (26),
abalgoitia et al. (27) found that the prevalence of LA/
AA thrombus in patients with AF was 3% in a low-risk
roup defined as an absence of all the following clinical risk
actors: women over age 75 years, hypertension, heart failure
r fractional shortening 25%, and prior thromboembo-
ism. In their study, 38% of patients in a low-risk group
ere anticoagulated and 28% had a history of PAF, whereas
ver 50% of patients with a CHADS2 score of 0 in our study
ere anticoagulated and had a history of PAF. Although
here is conflicting evidence, it was clearly shown that, in a
tudy population of AF patients undergoing TEE before
VI, no patients with a CHADS2 score of 0 had LA/LAA
hrombus or sludge. Furthermore, our study population was
n a lower-risk group than those undergoing DCC. Our
tudy suggests that PVI may be performed safely without
EE in patients with a CHADS2 score of 0 who received
eriprocedural warfarin therapy. Patients with PAF who are
n sinus rhythm at the time of PVI appear to be at lower
isk, but TEE should still be considered with a CHADS2
core 1.
The recent Heart Rhythm Society Task Force document
ound no consensus regarding the need to perform a TEE
creening before PVI in patients with PAF who are in sinus
hythm at the time of ablation (6). In our study, 1 patient
0.5%) with a history of PAF who was in sinus rhythm at
he time of PVI had LA/LAA sludge identified on a
creening TEE before PVI. However, this patient had
arfarin discontinued before the procedure. Furthermore, 1
atient with PAF who was in sinus rhythm at the time of
EE was found to have LA/LAA thrombus. The PVI
rocedure was cancelled due to LAA thrombus. The INR
n the day of TEE was 1.8. This illustrates that using a
linical history of PAF and rhythm at the time of PVI/TEE
lone may not completely exclude the thrombogenic state of
AA sludge and thrombus. Rather, combining a CHADS2
core as well as adequacy of anticoagulation with a history of
AF and sinus rhythm at time of PVI is more useful in
itigating a need of pre-PVI TEE screening.
elationship of CHADS2 score and TEE features of the
hrombogenic milieu. Previous studies have shown that
he prevalence of LA/LAA thrombus increased with an
ncreasing prevalence of clinical risk factors (11,27–31) and
higher CHADS2 score (26). Our findings agreed with
hose studies. The most powerful predictors of LA/LAA
ludge/thrombus in our study included impaired left ven-
ricular function and a history of CHF, which were in
greement with other studies (11,26,27,29–31) despite
ifferent study populations. In our study, patients with
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CHADS2 Score and TEE in Pulmonary Vein Isolation November 24, 2009:2032–9A/LAA sludge or thrombus had at least 1 clinical risk
actor of a CHADS2 score. Thus, those patients with at
east 1 clinical risk factor of CHADS2 score as well as a
istory of CHF and LVEF 35% should receive a
creening TEE to exclude LA/LAA sludge and thrombus
efore PVI.
elationship of TEE features of the thrombogenic mi-
ieu and subsequent thromboembolic events. There have
een conflicting data pertaining to the association between
A thrombus and thromboembolic stroke/events. In our
tudy, we found that patients with LA thrombus/sludge on
EE had insignificantly higher subsequent thromboem-
olic events; however, our study was underpowered for
troke. Our findings were concordant with the study by
rcher et al. (32). They also did not find the significant
ssociation between LA thrombus and embolic events
stroke/TIA and peripheral embolism) in patients with
hronic nonrheumatic valvular AF. They reported stroke
n 1 of 5 (20%) subjects with LA thrombus compared
ith an embolic event in 6 of 50 (12%) patients without
A thrombus during a mean follow-up duration of 34
onths. The study was underpowered to reach statistical
ignificance, and LA thrombus was not assessed by
ultivariate analysis as an independent predictor of
hromboembolic events. In a TEE substudy of the Stroke
revention in Atrial Fibrillation-III trial, a multivariate
nalysis examining TEE parameters failed to demon-
trate an independent predictor of LA thrombus for
mbolic events in 192 patients with nonvalvular AF (33).
he prevalence of LA thrombus in this study was 14%.
owever, in this trial, univariate analysis showed an
ssociation between embolism and LA thrombus. Fur-
hermore, Stollberger et al. (34) showed that LA throm-
us insignificantly (p  0.09) predicts stroke or periph-
ral embolism in patients with AF. In this study, the
ncidence of LA thrombus was 2.5% (34). However,
toddard et al. (35) recently demonstrated that LA
hrombus significantly predicts TIA in 261 patients with
F during a mean follow-up duration of 30 months. The
ncidence of LA thrombus in their study was 18%.
tudy limitations. This was a retrospective study. The
efinition of sludge was relatively subjective; nevertheless,
nterobserver variability in our study was very low among
hose TEE characteristics. We did not grade SEC as mild
r severe. TEEs were performed by various echocardio-
raphers; however, they were all specialized and experienced
n TEE. A CHADS2 score has not been validated in
atients with AF undergoing pre-PVI TEE, although it was
seful in excluding LA/LAA thrombus and sludge in those
ith a CHADS2 score of 0. The data for the adequacy of
nticoagulation were limited in this study and may have
ffected the features of the thrombogenic milieu. There was
eterogeneity of aggressiveness of anticoagulation and/or
arget-achieved INR before ablation. These were primarily
ased on the judgment of each electrophysiologist. Clinical
sefulness of the CHADS2 score in patients with AFndergoing PVI in this study was tested in patients treated
s they were at our site. This needs to be further tested in a
imilar patient population treated with a different anticoag-
lation protocol.
onclusions
ur study shows that the prevalence of LA/LAA sludge/
hrombus in patients with AF undergoing a pre-PVI
creening TEE is very low (0.6% for thrombus and 1.5% for
ludge) and significantly increases in patients with higher
HADS2 scores. This suggests that a more selective TEE
pproach to target high-risk patients may be beneficial. The
esults of our study demonstrate that a screening TEE
efore PVI should be performed in patients with a
HADS2 score 1 regardless of the rhythm at the time of
he procedure, and in patients with a CHADS2 score of 0
hen the therapeutic anticoagulation has not been main-
ained for 4 weeks before the procedure.
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Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk
15, Cleveland, Ohio 44195. E-mail: kleina@ccf.org.
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